Welcome to our dedicated page for NOVONIX SEC filings (Ticker: NVX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
NOVONIX Limited (NASDAQ: NVX, ASX: NVX) files reports with the U.S. Securities and Exchange Commission as a foreign private issuer under Commission File Number 001-41208. On this SEC filings page, Stock Titan surfaces NOVONIX’s regulatory submissions, including Form 6-K current reports that transmit key corporate documents and market announcements.
NOVONIX’s recent Form 6-K filings reference items such as applications for quotation of securities (Appendix 2A), notifications of cessation of securities (Appendix 3H), notifications of issue or conversion of unquoted equity securities (Appendix 3G), changes in substantial holdings, and quarterly activities and cash flow reports. These documents provide detail on NOVONIX’s capital structure changes, equity issuance or cessation events, and operational and cash flow updates.
The company’s filings also identify its principal executive office in Brisbane, Queensland, Australia, and confirm its status as a foreign issuer with securities listed on NASDAQ. Through these filings, NOVONIX reports on matters connected to its battery materials and technology activities, including synthetic graphite manufacturing projects and related financing or governance actions disclosed to investors via attached exhibits.
On Stock Titan, NOVONIX filings are paired with AI-powered summaries that highlight the main points of each document in accessible language. Users can quickly see what type of filing NOVONIX has submitted, the nature of any security issuances or changes, and references to significant corporate announcements included as exhibits. Real-time updates from the EDGAR system, combined with these summaries, help readers navigate NOVONIX’s regulatory history and understand how its SEC reporting aligns with its broader business developments.
NOVONIX Ltd director Robert J. Natter reported internal transfers of company shares between accounts he beneficially owns. On the reported date, three “J” code transactions moved a total of 460,686 ordinary shares among direct holdings and family trusts at a stated price of $0.0000 per share.
A footnote explains these were administrative transfers and did not change his overall economic interest in NOVONIX securities. He also holds share rights over 195,938 underlying ordinary shares with a stated exercise price of $0.0000 and an expiration date of December 31, 2027.
NOVONIX Ltd director Tony Bellas reported his derivative holdings of share rights linked to ordinary shares. The filing shows 195,938 underlying ordinary shares tied to these share rights at an exercise price of $0.0000 per share, exercisable from December 31, 2026 and expiring on December 31, 2027. No purchases or sales were reported; this entry updates his position in these rights.
NOVONIX Ltd director Jean Oelwang reported a derivative holding of 195,938 share rights linked to ordinary shares. These share rights have an exercise price of $0.0000 and are scheduled to expire on December 31, 2027. The filing shows 195,938 underlying ordinary shares associated with this position, with no buy or sell transactions indicated in the provided data.
NOVONIX Ltd director Ronald C. Edmonds reported his holdings of share rights linked to the company’s ordinary shares. The filing shows share rights over 195,938 underlying ordinary shares with an exercise price of $0.00 per share, exercisable from December 31, 2026 and expiring on December 31, 2027. This entry reflects a reported position rather than a new purchase or sale.
NOVONIX Ltd director Burrow Sharan reported a holding of 195,938 share rights linked to ordinary shares. These rights have a zero exercise price and are scheduled to become exercisable on December 31, 2026, with an expiration date of December 31, 2027. The filing reflects a position update rather than a new buy or sell transaction.
Novonix Limited filed a Form 6-K providing several ASX Appendix 3Y notices that record changes in directors’ interests. The changes mainly reflect the issue of 195,938 share rights to multiple directors following shareholder approval at the AGM on 15 April 2026. For example, Ron Edmonds now holds 416,342 ordinary shares and 195,938 share rights, while Sharan Burrow holds 215,739 ordinary shares and 195,938 share rights. These changes are described as issues of share rights rather than trades during a closed period.
NOVONIX LIMITED has issued 1,371,566 new unquoted Share Rights as a separate security class. These rights were not issued for cash consideration and will rank equally in all respects from their issue date of 6 May 2026.
The Share Rights form a new, unquoted ASX security class and increase NOVONIX’s unquoted securities alongside existing performance rights, options, convertible notes and convertible debentures. The issue is being put to security holders for approval under ASX Listing Rule 7.1 at a meeting dated 15 April 2026.
NOVONIX Ltd director and Chief Executive Officer Michael O'Kronley reported his existing derivative holdings in the form of performance rights. These rights relate to 5,862,567 underlying ordinary shares, have an exercise price of $0.0000, become exercisable on December 31, 2028, and expire on December 31, 2029. The entry is recorded as a holding, with no buy or sell transaction reported.
Novonix Limited filed a Form 6-K that includes an ASX Appendix 3Y detailing a change in director interests for Michael O’Kronley. The filing records the issue of performance rights to the director following shareholder approval at the AGM held on 15 April 2026.
After this change, Michael O’Kronley holds 9,586,538 performance rights. The notice also confirms that the interests were not traded during a closed period, so no special trading clearance was required.
Novonix Limited reported the issue of 5,862,567 unquoted NVXAD performance rights on May 5, 2026 under an employee incentive scheme. These rights were issued to key management personnel member Michael O'Kronley and are not intended to be quoted on ASX.
After this grant, Novonix has 861,442,940 NVX ordinary fully paid shares on issue, 35,021,775 NVXAD performance rights, 14,016,667 NVXAA options and 45,221,586 NVXAL convertible notes outstanding. The issue relied on exception 13 in ASX Listing Rule 7.2, so did not require separate security holder approval.